### Comprehensive Ideas for Promoting OncoMind

Based on our conversation, here's a full compilation of my ideas for promoting your tool. I've organized them into categories for clarity: **core strategy**, **content & messaging**, **channels & formats**, **differentiation & positioning**, **potential risks & mitigations**, and **next steps**. These build on the examples and drafts we've discussed, emphasizing OncoMind's strengths as a **research ideation tool** (not clinical), its **POC status** (messy code, early stage), and its unique value in turning evidence gaps into actionable study ideas.

The goal is to attract the right audience: postdocs, junior PIs, rare-cancer researchers, computational biologists — people who need quick inspiration for grants/papers when data is sparse. Avoid hype; lean into honesty, utility, and community feedback.

#### 1. Core Strategy
- **Narrow your audience**: Focus on academic/research users in precision oncology. Ignore clinicians — reinforce "research-only" everywhere to avoid misuse.
- **Emphasize POC honesty**: Call out the rough edges (e.g., "code is messy") upfront. This builds trust and invites collaboration (e.g., "DM for repo if you want to improve it").
- **Lead with value, not tech**: Don't sell "AI/LLM" — sell the problem solved: "From 'limited evidence' to 15+ study ideas in seconds."
- **Start small & iterate**: Launch with 1–2 posts on LinkedIn/X, a basic GitHub repo, and a waitlist form. Use feedback to refine (e.g., add more examples).
- **Free tier first**: Make it accessible (e.g., web demo with limited queries) to get users hooked, then explore premium features (e.g., custom integrations).
- **Collaborate early**: Reach out to rare-cancer groups (e.g., Cholangiocarcinoma Foundation) or bioinformatics communities (e.g., Reddit r/bioinformatics) for beta testing/case studies.

#### 2. Content & Messaging
- **Taglines** (use one consistently):
  - "From evidence gaps to study ideas — for researchers, not clinicians."
  - "When databases stop at 'limited evidence', we suggest what to test next."
  - "POC tool for research ideation in rare variants: models, screens, trials — messy code, useful outputs."
- **Key stories/examples**:
  - Hero case: PIK3CA H1047R in cholangiocarcinoma (minimal evidence → high priority → long list of ideas like isogenic models + basket trials).
  - Contrast case: BRAF V600E in colorectal (comprehensive evidence → low priority → modest confirmatory suggestions).
  - IDH1 H1047R in cholangiocarcinoma (similar to PIK3CA — shows consistency in low-evidence handling).
  - Always include screenshots (gap analysis + suggested studies) to show "before/after".
- **Disclaimers** (include in every post/material):
  - "Explicitly **not** for clinical use or treatment decisions."
  - "POC only — code is rough, expect bugs."
  - "Verify all suggestions against primary sources."
- **Case study format** (for blog/posts):
  - Input: Variant + tumor.
  - Standard databases: What they say (e.g., OncoKB: limited, breast-only).
  - OncoMind: Gap analysis + priority + 3–5 highlighted study ideas.
  - Why it matters: "Saves hours brainstorming aims for grants/papers."
- **Testimonials/feedback loop**: After sharing, ask "Would you use this? What variant would you test?" to generate quotes.

#### 3. Channels & Formats
- **LinkedIn** (primary channel — professional audience):
  - Post 1–2x/week: Short examples with screenshots, taglines, questions for engagement.
  - Groups: Precision Oncology, Cancer Research, Bioinformatics.
  - Influencers: Tag oncology researchers (e.g., those posting about rare variants).
- **X/Twitter** (for quick buzz):
  - Threads: 3–5 posts showing one example (gap → ideas) + POC disclaimer.
  - Hashtags: #CancerResearch #PrecisionOncology #RareCancers #Bioinformatics #ResearchTools.
  - Engage: Reply to posts about understudied variants with "Here's what my POC tool suggests..."
- **GitHub Repo** (core home):
  - README: Tagline + 2–3 examples + disclaimers + "How to run" (simple setup).
  - Issues: Use for feedback/bug reports.
  - Stars: Aim for 50–100 by sharing in communities.
- **Other low-effort channels**:
  - Reddit: r/bioinformatics, r/oncology, r/labrats — post as "Sharing my POC tool for variant research ideation".
  - bioRxiv/arXiv: Short methods paper ("LLM-assisted hypothesis generation for low-evidence oncology variants").
  - Newsletters: Submit to Bio-IT World or Precision Oncology News as "tool spotlight".
  - Conferences: ASCO, AACR posters/demos (virtual if budget low).
- **Formats to create**:
  - 1-slide pitch: Before (empty database) vs After (gap analysis + ideas).
  - Demo video: 1–2 min screen record (input variant → output studies).
  - Blog posts: "3 variants where databases fail but research must continue".

#### 4. Differentiation & Positioning
- **Vs OncoKB/CIViC**: "They tell you what's known clinically. We tell you what to study next when nothing is known."
- **Vs general LLMs**: "No hallucinations — gap-driven, structured suggestions."
- **Vs other research tools**: "Focused on rare/low-evidence cases; generates full study ladders (bench → trial ideas)."
- **POC as asset**: "Rough code means it's real and improvable — collaborate if interested."
- **Unique value prop**: "For the 90% of variants that aren't BRAF V600E or KRAS G12D — when you need ideas despite silence."

#### 5. Potential Risks & Mitigations
- **Risk**: Misuse as clinical tool.  
  - Mitigation: Bold disclaimers everywhere; redirect to OncoKB.
- **Risk**: Over-promising (e.g., "solves all gaps").  
  - Mitigation: Always say "POC", "ideas only — verify", "not polished".
- **Risk**: Low engagement (niche audience).  
  - Mitigation: Start with targeted shares (e.g., DM 5–10 researchers you follow).
- **Risk**: Code bugs discourage users.  
  - Mitigation: Set expectations low; offer "DM for help running it".
- **Risk**: IP/copycats.  
  - Mitigation: Open-source with license; focus on community building.

#### 6. Next Steps / Timeline
- **Day 1–3**: Polish 1–2 posts (use drafts I gave). Share on LinkedIn/X with screenshots.
- **Week 1**: Set up GitHub repo with README + examples. Add waitlist form (Google Forms) for demos.
- **Week 2**: Reach out to 3–5 contacts (e.g., rare-cancer researchers) for feedback.
- **Ongoing**: Collect user examples; iterate based on what resonates (e.g., more examples like IDH1).
- **Measure success**: 10–20 engagements on first post; 5–10 repo stars; 1–2 feedback DMs.

This is all the ideas I have — focused, actionable, and true to what your tool is. If you want me to draft a full README.md file or expand on any part, just say.


------------------
LinkedIn
Precision oncology databases are great… until they say “limited evidence” for your exact variant + tumor.

Then what?

OncoMind is my attempt to answer that question — for research only.

It’s not a clinical tool. It’s a hypothesis generator.

Input: PIK3CA H1047R in cholangiocarcinoma  
Output: minimal evidence → high research priority + a full list of doable next steps (isogenic models, organoids, ctDNA monitoring, retrospective series, basket trial ideas…)

Designed for researchers who need to propose experiments and studies when the data is sparse.

Curious if this would help your workflow — what variant/cancer would you test it on?

#CancerResearch #PrecisionMedicine #RareTumors

[screenshots]

Honest LinkedIn
POC alert: code is currently a mess 😅

But even in this rough state, it’s doing something useful:

Takes a variant with almost no tumor-specific data (e.g. PIK3CA H1047R in cholangiocarcinoma) → flags minimal evidence + high research priority → generates a list of realistic next steps (isogenic models, organoids, ctDNA monitoring, basket trial ideas, retrospective series…).

Explicitly **not** a clinical tool.  
Explicitly **not** polished software.  
Just a scrappy research ideation helper for when the literature and databases leave you hanging.

If you’re in rare-variant / rare-cancer research, does this kind of output save you any time?

Curious to hear.

#PrecisionOncology #CancerResearch

[screenshots]